The majority of CH clones pre-aHSCT were conserved throughout the transplant process, as patients with CH-derived tMN were more likely to have detectable CH prior to the procedure (78 vs. 10%, OR 31.5, P < 0.001) than the non-CH tMN patients (Fig. 4A). Here, C4B is linked to cyclic hematopoiesis.